Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial

CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research